Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Cancers
•
Medical Oncology
For a patient with high-risk metastatic endometrial cancer treated with neoadjuvant chemotherapy followed by surgery, would you offer adjuvant therapy if there is evidence of residual disease?
Related Questions
What adjuvant treatment would you recommend for a patient with FIGO 2023 IIIB2 endometrioid endometrial adenocarcinoma (Grade 3, p53mut, MMR proficient), metastatic to the uterine serosa, bilateral ovaries, and anterior peritoneal reflection?
In a patient with oligometastatic, recurrent Grade 2, ER+, MSI-high endometrioid adenocarcinoma who has a single, resectable metastasis to bone, what systemic therapy would you recommend and how would you time it in relation to possible surgery?
Would you recommend PARP inhibitor maintenance for a patient with HR-proficient ovarian cancer with no targetable mutation, but with a favorable KELIM score and a significant clinical, radiographic, and serological response to platinum-based chemotherapy?
Do you recommend concurrent cisplatin and gemcitabine with radiotherapy for unresectable vulvar cancer, as described in GOG-279?
What would you offer a patient with MSI-high metastatic endometrial cancer after disease progression on pembrolizumab?
How would you manage a recurrent cervical cancer previously treated with vaginal cuff brachytherapy and has had a complete response to chemo-immunotherapy?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
How would you manage a cervical cancer patient with bulky PA LNs with direct extension and/or invasion into the lumbar vertebral bodies?
What are your top takeaways from SGO 2024?
